Gender differences in the cardiovascular effects of sex hormones

Fundamental and Clinical Pharmacology

Volumn 24, Issue 6, 2010, Pages 675-685

  Vitale, Cristiana ^a,b   Fini, Massimo ^a,b   Speziale, Giuseppe ^a,b   Chierchia, Sergio ^a,b  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b Anthea Hospital GVM Care and Research   (Italy)

Author keywords

Cardiovascular disease; Gender; Hormone replacement therapy; Oestrogens; Sex hormones; Testosterone

Indexed keywords

ANDROGEN; ESTROGEN; GESTAGEN; GLUCOSE; SEX HORMONE; TESTOSTERONE;

ACUTE HEART INFARCTION; ANDROGEN THERAPY; ANGINA PECTORIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ESTROGEN THERAPY; GLUCOSE METABOLISM; HEART PROTECTION; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; NONHUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEX DIFFERENCE; SEXUAL DYSFUNCTION;

CARDIOVASCULAR DISEASES; ESTROGENS; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; SEX FACTORS; TESTOSTERONE;

EID: 78349252740     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00817.x     Document Type: Review

References (120)

1. Kannel W.B., Hjortland M.C., McNamara P.M. et al. Menopause and risk of cardiovascular disease: the Framingham study. Ann. Intern. Med. (1976) 85 447-452.
2. Liu Y., Ding J., Bush T.L. et al. Relative androgen excess and increased cardiovascular risk after menopause: a hypothesized relation. Am. J. Epidemiol. (2001) 154 489-494.
3. Wild S., Pierpoint T., McKeigue P., Jacobs H.S. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin. Endocrinol. (Oxf) (2000) 52 595-600.
4. Orshal J.M., Khalil R.A. Gender, sex hormones, and vascular tone. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 286 R233-R249.
5. Mendelsohn M.E., Rosano G.M. Hormonal regulation of normal vascular tone in males. Circ. Res. (2003) 93 1142-1145.
6. Mendelsohn M.E., Karas R.H. Molecular and cellular basis of cardiovascular gender differences. Science (2005) 308 1583-1587.
7. Crews J.K., Khalil R.A. Gender-specific inhibition of Ca2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin. Exp. Pharmacol. Physiol. (1999) 26 707-715.
8. Kanashiro C.A., Khalil R.A. Gender-related distinctions in protein kinase C activity in rat vascular smooth muscle. Am. J. Physiol. Cell Physiol. (2001) 280 C34-C45.
9. Mendelsohn M.E., Karas R.H. The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med. (1999) 340 1801-1811.
10. Mendelsohn M.E. Protective effects of estrogen on the cardiovascular system. Am. J. Cardiol. (2002) 89 12E-18E.
11. Mendelsohn M.E. Genomic and nongenomic effects of estrogen in the vasculature. Am. J. Cardiol. (2002) 90 3F-6F.
12. Collins P., Rosano G.M., Sarrel P.M. et al. 17 Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation (1995) 92 24-30.
13. Chambliss K.L., Yuhanna I.S., Anderson R.G., Mendelsohn M.E., Shaul P.W. ER b has non-genomic action in caveolae. Mol. Endocrinol. (2002) 16 938-946.
14. Chen Z., Yuhanna I.S., Galcheva-Gargova Z., Karas R.H., Mendelsohn M.E., Shaul P.W. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. (1999) 103 401-406.
15. Meyer M.R., Haas E., Barton M. Gender differences of cardiovascular disease: new perspectives for estrogen receptor signaling. Hypertension (2006) 47 1019-1026.
16. Haas E., Bhattacharya I., Brailoiu E. et al. Regulatory role of g protein-coupled estrogen receptor for vascular function and obesity. Circ. Res. (2007) 104 288-291.
17. Pare G., Krust A., Karas R.H. et al. Estrogen receptor-α mediates the protective effects of estrogen against vascular injury. Circ. Res. (2002) 90 1087-1092.
18. Hodgin J.B., Krege J.H., Reddick R.L. et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J. Clin. Invest. (2001) 107 333-340.
19. Zhu Y., Bian Z., Lu P. et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science (2002) 295 505-508.
20. Hodges Y.K., Tung L., Yan X.D., Graham J.D., Horwitz K.B., Horwitz L.D. Estrogen receptors alpha and beta: prevalence of estrogen receptor beta mRNA in human vascular smooth muscle and transcriptional effects. Circulation (2000) 101 1792-1798.
21. Nakamura Y., Suzuki T., Sasano H. Estrogen actions and in situ synthesis in smooth muscle cells and their correlation with atherosclerosis. J. Steroid Biochem. Mol. Biol. (2005) 93 263-268.
22. Post W.S., Goldschmidt-Clermont P.J., Wilhide C.C. et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. Cardiovasc. Res. (1999) 43 985-991.
23. Vitale C., Mercuro G., Cerquetani E. et al. Time since menopause influences the acute and chronic effect of estrogens on endothelial function. Arterioscler. Thromb. Vasc. Biol. (2008) 28 348-352.
24. Volterrani M., Rosano G., Coats A., Beale C., Collins P. Estrogen acutely increases peripheral blood flow in postmenopausal women. Am. J. Med. (1995) 99 119-122.
25. Rosano G.M., Gebara O., Sheiban I. et al. Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia. Int. J. Cardiol. (2006) 116 34-39.
26. Adamopoulos S., Rosano G.M., Ponikowski P. et al. Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. Am. J. Cardiol. (1998) 82 862-868.
27. Sudhir K., Chou T.M., Messina L.M. et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet (1997) 349 1146-1147.
28. Sudhir K., Chou T.M., Chatterjee K. et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation (1997) 96 3774-3777.
29. Carani C., Qin K., Simoni M. et al. Effect of testosterone and of estradiol in a man with aromatase deficiency. N. Engl. J. Med. (1997) 337 91-95.
30. Smith E.P., Boyd J., Frank G.R. et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N. Engl. J. Med. (1994) 331 1056-1061.
31. Lew R., Komesaroff P., Williams M., Dawood T., Sudhir K. Endogenous estrogens influence endothelial function in young men. Circ. Res. (2003) 93 1127-1133.
32. Kneale B.J., Chowienczyk P.J., Brett S.E., Coltart D.J., Ritter J.M. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J. Am. Coll. Cardiol. (2000) 36 1233-1238.
33. Wu F.C., Von Eckardstein A. Androgens and coronary artery disease. Endocr. Rev. (2003) 24 183-217.
34. Liu P.Y., Death A.K., Handelsman D.J. Androgens and cardiovascular disease. Endocr. Rev. (2003) 24 313-340.
35. Yildiz O., Seyrek M. Vasodilating mechanisms of testosterone. Exp. Clin. Endocrinol. Diabetes (2007) 115 1-6.
36. Yildiz O., Seyrek M., Gul H. et al. Testosterone relaxes human internal mammary artery in vitro. J. Cardiovasc. Pharmacol. (2005) 45 580-585.
37. Von Eckardstein A., Wub F.C.W. Testosterone and atherosclerosis. Growth Horm. IGF Res. (2003) 13 S72-S84.
38. English K.M.J.R., Jones T.H., Morice A.H., Channer K.S. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J. Endocrinol. Invest. (2002) 25 455-458.
39. Jones R.D., Hugh Jones T., Channer K.S. The influence of testosterone upon vascular reactivity. Eur. J. Endocrinol. (2004) 151 29-37.
40. Herman S.M., Robinson J.T.C., McCredie R.J., Adams M.R., Boyer M.J., Celermajer D.S. Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler. Thromb. Vasc. Biol. (1997) 17 2004-2009.
41. Webb C.M., Adamson D.L., De Zeigler D., Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am. J. Cardiol. (1999) 83 437-439.
42. Kang S.-M., Jang Y., Kim J.-Y. et al. Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am. J. Cardiol. (2002) 89 862-864.
43. English K.M., Mandour O., Steeds R.P., Diver M.J., Jones T.H., Channer K.S. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur. Heart J. (2000) 21 890-894.
44. Rosano G.M.C., Leonardo F., Pagnotta P. et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation (1999) 6 1666-1670.
45. Kenny A.M., Prestwood K.M., Gruman C.A., Fabregas G., Biskup B., Mansoor G. Effects of transdermal testosterone on lipids and vascular reactivity in older men with low bioavailable testosterone levels. J. Gerontol. A Biol. Sci. Med. Sci. (2002) 57 M460-M465.
46. McCrohon J.A., Death A.K., Nakhla S. et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation (2000) 101 224-226.
47. McCredie R.J., McCrohon J.A., Turner L., Griffiths K.A., Handelsman D.J., Celermajer D.S. Vascular reactivity is impaired in genetic females taking high dose androgens. J. Am. Coll. Cardiol. (1998) 32 1331-1335.
48. Worboys S., Kotsopoulos D., Teede H., McGrath B., Davis S.R. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J. Clin. Endocrinol. Metab. (2001) 86 158-161.
49. Appt S.E., Clarkson T.B., Lees C.J., Anthony M.S. Low dose estrogens inhibit coronary artery atherosclerosis in postmenopausal monkeys. Maturitas (2006) 55 187-194.
50. Clarkson T.B., Antony M.S., Klein K.P. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br. J. Obstet. Gynaecol. (1996) 103 53-57.
51. Cann J.A., Register T.C., Adams M.R., St Clair R.W., Espeland M.A., Williams J.K. Timing of estrogen replacement influences atherosclerosis progression and plaque leukocyte populations in ApoE-/- mice. Atherosclerosis (2008) 201 43-52.
52. Lakoski S.G., Brosnihan B., Herrington D.M. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am. Heart J. (2005) 150 907-911.
53. Hodis H.N., Mack W.J., Azen S.P. et al. Women's Estrogen-Progestin Lipid-Lowering Hormone Atherosclerosis Regression Trial Research Group Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N. Engl. J. Med. (2003) 349 535-545.
54. Manson J.E., Allison M.A., Rossouw J.E. et al. Estrogen therapy and coronary-artery calcification. N. Engl. J. Med. (2007) 356 2591-2602.
55. Mendelsohn M.E., Karas R. HRT and the young at heart. N. Engl. J. Med. (2007) 21 2639-2641.
56. Arnal J.F., Scarabin P.Y., Tremollieres F., Laurell H., Gourdy P. Estrogens in vascular biology and disease: where do we stand today? Curr. Opin. Lipidol. (2007) 18 554-560.
57. Mikkola T.S., Clarkson T.B. Estrogen replacement therapy, atherosclerosis, and vascular function. Cardiovasc. Res. (2002) 53 605-619.
58. Sztejnsznajd C., Da Silva M.E., Nussbacher A. et al. Estrogen treatment improves arterial distensibility, fibrinolysis, and metabolic profile in postmenopausal women with type 2 diabetes mellitus. Metabolism (2006) 55 953-959. Erratum in: Metabolism (2006) Oct 55(10) 1435.
59. Da Costa L.S., De Oliveira M.A., Rubim V.S. et al. Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am. J. Cardiol. (2004) 94 1453-1456.
60. Alexandersen P., Haarbo J., Byrjalsen I., Lawaetz H., Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ. Res. (1999) 84 813-819.
61. Obasanjo I.O., Clarkson T.B., Weaver D.S. Effects of the anabolic steroid nandrolone decanoate on plasma lipids and coronary arteries of female cynomolgus macaques. Metabolism (1996) 45 463-468.
62. Nathan L., Shi W., Dinh H. et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc. Natl Acad. Sci. USA (2001) 98 3589-3593.
63. Arad Y., Badimon J.J., Badimon L., Hembree W.C., Ginsberg H.N. Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis (1989) 9 159-166.
64. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch. Intern. Med. (2006) 166 1660-1665.
65. Laughlin G.A., Barrett-Connor E., Bergstrom J. Low serum testosterone and mortality in older men. J. Clin. Endocrinol. Metab. (2008) 93 68-75.
66. Khaw K.T., Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation (2007) 116 2694-2701.
67. Phillips G.B., Pinkernell B.H., Jing T.Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler. Thromb. (1994) 14 701-706.
68. Barret-Connor E. Andropause and intima media thickness. J. Am. Coll. Cardiol. (2005) 45 1609-1610.
69. Rosano G.M., Sheiban I., Massaro R. et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int. J. Impot. Res. (2007) 19 176-182.
70. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet. Gynecol. Scand. (1992) 71 599-604.
71. Barrett-Connor E., Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation (1995) 91 1757-1760.
72. Van Kesteren P., Asscheman H., Megens J.A.J., Gooren L.J.G. Mortality and morbidity in transsexual subjects treated with cross sex hormones. Clin. Endocrinol. (Oxf) (1997) 47 337-342.
73. Barrett-Connor E.L., Cohn B.A., Wingard D.L., Edelstein S.L. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA (1991) 265 627-631.
74. Ding E.L., Song Y., Malik V.S., Liu S. Meta-analysis of type 2 diabetes: a systematic review and sex differences of endogenous sex hormones and risk. JAMA (2006) 295 1288-1299.
75. Meriggiola M.C., Marcovina S., Paulsen C.A., Bremner W.J. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men. Int. J. Androl. (1995) 18 237-242.
76. Haffner S.M., Ksuhwaha R.S., Foster D.M., Applebaum-Bowden D., Hazzard W.R. Studies on the metabolic mechanism of reduced high density lipoprotein during anabolic steroid therapy. Metabolism (1983) 32 413-417.
77. Enzi G.B., Giada F., Zuliani G. et al. Lipid and apoprotein modifications in body builders during and after self administration of anabolic steroids. Metabolism (1990) 39 203-208.
78. Kantor M.E., Bianchini A., Bernier D., Sady S.P., Thompson P.D. Androgens reduce HDL-2 cholesterol and increse hepatic triglyceride lipase activity. Med. Sci. Sports Exerc. (1985) 17 462-465.
79. Asscherman H., Gooren L.J.G., Megens J.A.J., Nauta J., Kloosterboer H.J., Eikelboom F. Serum testosterone is the major determinant of male-female differences in serum levels of high-density lipoprotein-cholesterol and HDL-2 cholesterol. Metabolism (1994) 43 935-939.
80. Assmann G., Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur. J. Epidemiol. (1992) 8 99-103.
81. Tikkanen M.J., Vihma V., Jauhiainen M. et al. Lipoprotein-associated estrogens. Cardiovasc. Res. (2002) 56 184-188.
82. Chikani G., Zhu W., Smart E.J. et al. Lipids: potential regulators of nitric oxide generation. Am. J. Physiol. Endocrinol. Metab. (2004) 287 E386-E389.
83. Hergenc G., Schulte H., Assmann G., Von Eckardstein A. Associations of obesity markers, insulin, and sex hormones with HDL-cholesterol levels in Turkish and German individuals. Atherosclerosis (1999) 145 147-156.
84. Tchernof A., Labrie F., Belanger A., Despres J.P. Obesity and metabolic complications: contribution of dehydroepiandrosterone and other steroid hormones. J. Endocrinol. (Suppl.) (1996) 150 S155-S164.
85. Tsai E.C., Boyko E.J., Leonetti D.L., Fujimoto W.Y. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int. J. Obes. Relat. Metab. Disord. (2000) 24 485-491.
86. Isidori A.M., Giannetta E., Greco E.A. et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin. Endocrinol. (Oxf) (2005) 63 280-293.
87. Kapoor D., Malkin C.J., Channer K.S., Jones T.H. Androgens, insulin resistance and vascular disease in men. Clin. Endocrinol. (Oxf) (2005) 63 239-250.
88. Tan K.C., Shiu S.W., Pang R.W., Kung A.W. Effects of testosterone replacement on HDL subfractions and apolipoprotein A-I containing lipoproteins. Clin. Endocrinol. (Oxf) (1998) 48 187-194.
89. Khaw K.T., Barrett-Connor E. Lower endogenous androgens predict central adiposity in men. Ann. Epidemiol. (1992) 2 675-682.
90. Poehlman E.T., Toth M.J., Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. [retraction in: Sox HC. Ann. Intern. Med. (2003) 139 702]. Ann. Intern. Med. (1995) 123 673-675.
91. Carr M.C. The emergence of the metabolic syndrome with menopause. J. Clin. Endocrinol. Metab. (2003) 88 2404-2411.
92. Tchernof A., Poehlman E.T., Despres J.P. Body fat distribution, the menopause transition, and hormone replacement therapy. Diabetes Metab. (2000) 26 12-20.
93. Simon D., Charles M.A., Naohul K., Orssaud G. Association between plasma testosterone and cardiovascular risk factors in healthy adult men. The Telecom Study. J. Clin. Endocrinol. Metab. (1997) 82 682-685.
94. Barrett-Connor E. Lower endogenous androgen levels dyslipidaemia in men with NIDDM. Ann. Intern. Med. (1992) 117 807-811.
95. Anderson G.L., Limacher M., Assaf A.R. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291 1701-1712.
96. Katznelson L., Finkelstein J.S., Schoenfeld D.A. et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J. Clin. Endocrinol. Metab. (1996) 81 4358-4365.
97. Ferrannini E., Natali A., Capaldo B. et al. Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension (1997) 30 1144-1149.
98. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ (2006) 332 73-78.
99. Steinberg H.O., Paradisi G., Cronin J. et al. Type II diabetes abrogates sex differences in endothelial function in premenopausal women. Circulation (2000) 101 2040-2046.
100. Lindheim S.R., Presser S.C., Ditkoff E.C., Vijod M.A., Stanczyk F.Z., Lobo R.A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil. Steril. (1993) 60 664-667.
101. Dunne F.P., Barry D.G., Ferriss J.B. et al. Changes in blood pressure during the normal menstrual cycle. Clin. Sci. (1991) 81 515-518.
102. Reckelhoff J.F. Gender differences in the regulation of blood pressure. Hypertension (2001) 37 1199-1208.
103. Sitruk-ware R.L. Hormone therapy and the cardiovascular system: the critical role of progestins. Climacteric (2003) 6 21-28.
104. Kienitz T., Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press. Res. (2008) 31 71-79.
105. Sullivan J.M., Vander Zwaag R., Hughes J.P. et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch. Intern. Med. (1990) 150 2557-2562.
106. Herrington D.M., Vittinghoff E., Lin F. et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation (2002) 105 2962-2967.
107. Hulley S., Grady D., Bush T. et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA (1998) 280 605-613.
108. Rossouw J.E., Anderson G.L., Prentice R.L. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 288 321-333.
109. Sowers M., Randolph J. Jr, Jannausch M. et al. Levels of sex steroid and cardiovascular disease measures in premenopausal and hormone-treated women at midlife. Implications for the timing hypothesis. Arch. Intern. Med. (2008) 168 2146-2153.
110. Ouyang P., Michos E.D., Karas R.H. Hormone replacement therapy and the cardiovascular system: lessons learned and unanswered questions. J. Am. Coll. Cardiol. (2006) 47 1741-1753.
111. Rossouw J.E., Prentice R.L., Manson J.E. et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 297 1465-1477.
112. Grodstein F., Manson J.E., Stampfer M.J. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J. Womens Health (Larchmt). (2006) 15 35-44.
113. Wright J., Naftolin F., Schneider H.P., Sturdee D.W. Executive Committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Position statement by the Executive Committee of the International Menopause Society. Maturitas (2004) 48 27-31.
114. Rosano G.M., Maffei S., Andreassi M.G. et al. Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J. Cardiovasc. Med. (Hagerstown). (2009) 10 85-92.
115. [No authors listed]. Factors influencing long-term prognosis after recovery from myocardial infarction - three-year findings of the coronary drug project. J. Chronic. Dis. (1974) 7 267-285.
116. Phillips G.B., Castelli W.P., Abbott R.D., McNamara P.M. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am. J. Med. (1993) 74 863-869.
117. Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N. Engl. J. Med. (2004) 350 482-492.
118. Braunstein G.D. Management of female sexual dysfunction in postmenopausal women by testosterone administration: safety issues and controversies. J. Sex. Med. (2007) 4 859-866.
119. Vitale C., Collins P., Marazzi G. Cardiovascular effects of transdermal testosterone in postmenopausal women. Circulation (2008) 118 S1137-S1138.
120. Caminiti G., Karam R., Volterrani M. et al. Effects of testosterone supplementation in elderly female patients with chronic heart failure. Eur. Heart J. (2008) 29 S769.